Northwest Pain Care, Spokane, WA, USA.
National Spine & Pain Center, National Harbor, MD, USA.
Neuromodulation. 2021 Apr;24(3):556-565. doi: 10.1111/ner.13324. Epub 2020 Dec 9.
Multiple variables play a role in spinal cord stimulation (SCS) treatment outcomes, including patient anatomy, pain pattern, lead location, stimulation parameters, and so on. A wide range of stimulation parameters are considered safe and on-label, and as a result a growing number of new frequencies and frequency-combinations are being incorporated into standard practice. A standardized approach to therapy delivery may provide more consistent outcomes for more patients. The Vectors study evaluated whether there is significant sustained improvement in pain and functional outcomes when therapy is delivered using a standardized approach.
Vectors, a post-market, single-arm study evaluated the safety and efficacy of SCS with an implantable neurostimulator starting with 1 kHz stimulation, targeting the T9-T10 disc space following paresthesia mapping. Subjects with chronic intractable low back and leg pain (visual analogue scale [VAS] ≥ 50 mm) were enrolled. The primary endpoint was change in overall pain (VAS) at the three-month visit compared to baseline. Subjects were followed through 12 months. Secondary endpoints included changes in low back and leg pain, quality of life (European Quality of Life - Five Dimensions, EQ-5D-5L), disability (Oswestry Disability Index, ODI), individual subject goals, and subject satisfaction.
There was a significant reduction in overall pain (VAS; 45.4 mm) through the three-month visit, which was sustained through 12 months. At 12 months, 79% of subjects had ≥50% improvement in at least one pain domain (overall, lowback or leg) with 85% of subjects reporting therapy satisfaction. There was a decrease in disability and an improvement in quality of life with 70% of subjects achieving a personal activity goal by the three-month visit.
Long-term pain relief and improvement in quality of life and function were achieved when following a standardized workflow.
The Clinicaltrials.gov registration number for the study is NCT03345472.
脊髓刺激(SCS)治疗效果受多种因素影响,包括患者解剖结构、疼痛类型、电极位置、刺激参数等。许多刺激参数被认为是安全且符合规定的,因此越来越多的新频率和频率组合被纳入标准治疗方案。采用标准化治疗方法可能会为更多患者带来更一致的治疗效果。Vectors 研究旨在评估在采用标准化治疗方法时,疼痛和功能结局是否会持续显著改善。
Vectors 是一项上市后、单臂研究,评估了使用植入式神经刺激器以 1 kHz 刺激开始、采用感觉定位图定位 T9-T10 椎间盘间隙的 SCS 的安全性和疗效。入组患者为患有慢性顽固性腰痛和下肢痛(视觉模拟评分[VAS]≥50 mm)的患者。主要终点为与基线相比,三个月访视时的总体疼痛(VAS)变化。患者接受了 12 个月的随访。次要终点包括腰痛和下肢痛、生活质量(欧洲五维健康量表,EQ-5D-5L)、残疾(Oswestry 残疾指数,ODI)、个体目标和患者满意度的变化。
通过三个月的访视,患者的总体疼痛(VAS)显著降低(45.4 mm),并在 12 个月时持续存在。12 个月时,至少有一个疼痛域(总体、腰痛或下肢痛)改善≥50%的患者占 79%,85%的患者报告对治疗满意。残疾程度降低,生活质量改善,70%的患者在三个月时达到个人活动目标。
遵循标准化工作流程可实现长期缓解疼痛,改善生活质量和功能。
该研究的 Clinicaltrials.gov 注册号为 NCT03345472。